Biomica Enters New Agreement with Biose Industrie for Scale-up and GMP Production of Drug Candidates BMC121 & BMC127 for its Immuno-Oncology Program
Evogene Ltd. - Ordinary Shares (EVGN)
Last evogene ltd. - ordinary shares earnings: 2/28 07:00 am
Check Earnings Report
US:NYSE Investor Relations:
evogene.com/investor-relations
Company Research
Source: PR Newswire
REHOVOT, Israel, Jan. 14, 2020 /PRNewswire/ -- Biomica, an emerging biopharmaceutical company developing innovative microbiome-based therapeutics, and a subsidiary of Evogene Ltd. (NASDAQ: EVGN) (TASE: EVGN), announced today that it has entered a service agreement with Biose Industrie, a France based CDMO, for the scale-up production of its drug candidates, microbial consortia BMC121 & BMC127 for its Immuno-Oncology program. This agreement will accelerate the Company's Immuno-Oncology program which is currently planned to enter the clinic in 2021 for proof of concept studies. Biose Industrie is a drug-GMP certified manufacturer of bacteria-based APIs and clinical and commercial products. Biomica engaged with Biose for the scale-up development and GMP production of a clinical batch of its drug candidates. As previously announced, BMC121 & BMC127 were recently evaluated in pre-clinical studies in a mouse cancer model under Biomica's immuno-oncology program, aiming to improve the effic
Show less
Read more
Impact Snapshot
Event Time:
EVGN
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EVGN alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EVGN alerts
High impacting Evogene Ltd. - Ordinary Shares news events
Weekly update
A roundup of the hottest topics
EVGN
News
- Evogene Reports Third Quarter 2024 Financial ResultsPR Newswire
- Lavie Bio Advances its Bio-Fungicide LAV321, Targeting Downy Mildew, to Pre-Commercial Stage Following Successful 2024 Field Trial Results [Yahoo! Finance]Yahoo! Finance
- Lavie Bio Advances its Bio-Fungicide LAV321, Targeting Downy Mildew, to Pre-Commercial Stage Following Successful 2024 Field Trial ResultsPR Newswire
- Evogene Ltd. (NASDAQ: EVGN) is now covered by analysts at StockNews.com. They set a "sell" rating on the stock.MarketBeat
- Lavie Bio Announces Commercial Expansion of Yalos® as Seed-Treatment for Soybean, Following Successful Field TrialsPR Newswire
EVGN
Earnings
- 3/7/24 - Beat
EVGN
Sec Filings
- 11/21/24 - Form 424B3
- 11/21/24 - Form 6-K
- 10/15/24 - Form SC
- EVGN's page on the SEC website